Investigational drug · Phase 2
MAX-40279
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "MAX-40279"
First trial start
2025
Sep 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MAX-40279", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "MAX-40279" as an intervention, largest first.
- A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal CancerPivotal-lookingStatus unknown
Maxinovel Pty., Ltd.Industry
NCT05130021 · 130 participants (planned) · Start Jan 31, 2022 · Primary completion May 30, 2022
Drug: MAX-40279-01; regorafenib · For: Metastatic Colorectal Cancer
Sites: Guangzhou, China
- A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid TumorsStatus unknown
Maxinovel Pty., Ltd.Industry
NCT05425602 · 108 participants (planned) · Start Jul 31, 2022 · Primary completion Dec 30, 2023
Drug: MAX-40279-01: 50mg/70mg · For: Advanced / Metastatic Solid Tumors
Maxinovel Pty., Ltd.Industry
NCT05061147 · 100 participants (planned) · Start Sep 16, 2021 · Primary completion Apr 30, 2022
Drug: MAX-40279-01 · For: Leukemia; Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia and 1 more
Sites: Tianjin, China
Maxinovel Pty., Ltd.Industry
NCT07743112 · 43 participants (planned) · Start Sep 5, 2025 · Primary completion Sep 1, 2027
Drug: MAX-40279; Azacitidine and 1 more · For: Acute Myeloid Leukemia
Sites: Tianjin, China
Maxinovel Pty., Ltd.Industry
NCT03412292 · 30 participants (planned) · Start Aug 1, 2018 · Primary completion Nov 1, 2022
Drug: MAX-40279 · For: Acute Myelogenous Leukemia (AML)
Sites: Darlinghurst, Australia; Dubbo, Australia; Clayton, Australia · 4 sites in all
- Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)Status unknown
Maxinovel Pty., Ltd.Industry
NCT04187495 · 30 participants (planned) · Start Apr 16, 2019 · Primary completion Dec 1, 2022
Drug: MAX-40279-01 · For: AML
Sites: Hangzhou, China
Maxinovel Pty., Ltd.Industry
NCT05395780 · 30 participants (planned) · Start Jun 2022 · Primary completion Dec 2022
Drug: MAX-40279 · For: Gastric Cancer; Gastroesophageal Junction Cancer
Sites: Nanjing, China
- MAX-40279-01 in Patients With Advanced Solid TumorsStatus unknown
Maxinovel Pty., Ltd.Industry
NCT04183764 · 30 participants (planned) · Start Nov 28, 2019 · Primary completion Nov 1, 2022
Drug: MAX-40279-01 · For: Solid Tumor
Sites: Hangzhou, China
- A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid TumorsStatus unknown
Maxinovel Pty., Ltd.Industry
NCT05369286 · 28 participants (planned) · Start Apr 11, 2022 · Primary completion May 31, 2023
Drug: "MAX-40279-01" and "Toripalimab" · For: Solid Tumor
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- The Trojan Horse system composed of platelet membrane and extracellular vesicles inhibits atherosclerotic plaque progression.
Ling L, Xue Z, Lv M, et al. · iScience 2026
- PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis.
Xue Z, Han M, Sun T, et al. · Theranostics 2025
Also in development for Acute Myeloid Leukemia
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- GM-CSFPhase 32 trials
Y-mAbs Therapeutics · Neuroblastoma, Acute Myeloid Leukemia
- HMPL-306Phase 32 trials
Hutchmed · Acute Myeloid Leukemia, Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RVU120SEL120Phase 23 trials
Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- IMGN632Phase 22 trials
AbbVie · Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.